Pionyr Immunotherapeutics is a clinical stage company developing cancer immunotherapies that target the tumor microenvironment to enhance the body’s antitumor immunity.
Total raised: $62M
Founded date: 2015
Investors 6
| Date | Name | Website |
| 06.07.2021 | New Enterp... | nea.com |
| - | Vida Ventu... | vidaventur... |
| - | Mission Bi... | missionbio... |
| - | Sofinnova ... | sofinnova.... |
| - | MBC BioLab... | mbcbiolabs... |
| - | SV Health ... | svhealthin... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.01.2018 | Series B | $62M | New Enterp... |
Mentions in press and media 17
| Date | Title | Description |
| 02.07.2024 | Steven James, Accomplished CEO and Biotech Executive, Joins Board of Directors of Rondo Therapeutics | HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately-held biopharmaceutical company advancing next-generation immuno-oncology platforms, announces the appointment of Steven James to its Board of Directors. Mr. James brings over... |
| 30.03.2021 | Pionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development | Quote from Henit Lapid, Head Mammalian Commercial Development and Marketing, Lonza: |
| 23.06.2020 | Gilead to buy 49.9% stake in biotech startup Pionyr Immunotherapeutics for $275M to secure access to two promising cancer drugs | Gilead Sciences announced Tuesday it would buy a 49.9% stake in biotech startup Pionyr Immunotherapeutics for $275 million. The investment would strengthen Gilead Sciences’ cancer portfolio by securing access to two promising drugs. As part... |
| 23.06.2020 | Gilead buys nearly 50% equity interest in cancer immunotherapy-focused Pionyr for $275M | Pionyr’s last major financing was in December 2017, when it closed a $62 million Series B financing round. The company’s pipeline page lists three product candidates, all in varying stages of preclinical development for solid tumor cancers:... |
| 23.06.2020 | Gilead Sciences To Acquire 49.9 % Equity In Pionyr Immunotherapeutics, For $275M | Gilead Sciences, Inc. (Nasdaq: GILD) will acquire a 49.9 % equity interest in Pionyr Immunotherapeutics Inc., a South San Francisco, CA-based company developing first-in-class cancer immunotherapies, for $275m. Gilead also acquired an exclu... |
| 10.01.2018 | Pionyr Immunotherapeutics Completes $62M Series B Financing | - |
| 14.12.2017 | Pionyr Immunotherapeutics Inks $62M Series B | SAN FRANCISCO, CA, Pionyr Immunotherapeutics announced the closing of a $62 million Series B investment round. >> Click here for more funding data on Pionyr Immunotherapeutics >> To export Pionyr Immunotherapeutics funding d... |
| 14.12.2017 | Term Sheet — Friday, December 14 | WHO BELONGS ON THE MT. RUSHMORE OF VCS? Good morning Term Sheet readers, this is Jeff John Roberts pinch-hitting for the popular Polina today. Paid Content Securing the enterprise without boundaries From ExtraHop There’s no plan afoot to ca... |
| 13.12.2017 | NEA Leads $62M Series B for Pionyr Immunotherapeutics | Pionyr Immunotherapeutics, Inc., a company developing antibody therapeutics that increase the body's antitumor immunity by rebalancing the myeloid infiltrate in the tumor microenvironment, announced the closing of a $62 million Series B inv... |
| 13.12.2017 | Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment | - |
Show more